Inquiry Basket
Loading ......
Filter By Product Search for
CLU
CLU Full Name
clusterin
CLU Introduction
Clusterin (CLU) is a highly conserved glycoprotein-encoding gene located on chromosome 8p21-p12 that produces multiple transcript and protein isoforms through alternative splicing and post-translational processing. The best-characterized forms include the secreted clusterin (sCLU), a heavily glycosylated heterodimeric protein found in many tissues and biological fluids, and the nuclear clusterin (nCLU), a less abundant isoform associated with pro-apoptotic activity. Researchers are increasingly interested in CLU because its expression rises dramatically in response to cellular stress, inflammation, oxidative damage, and tissue injury. Acting as an extracellular molecular chaperone, CLU helps maintain protein homeostasis by preventing protein aggregation, regulating lipid transport, modulating complement activation, and protecting cells from environmental and metabolic stress. These diverse biological properties have positioned CLU as a critical biomarker and therapeutic target in studies focused on aging, tissue remodeling, and chronic disease progression.
From a functional perspective, CLU serves as a multifunctional regulator of cell survival, apoptosis, immune responses, and tissue repair. Secreted CLU generally exerts cytoprotective effects by stabilizing misfolded proteins, limiting inflammatory damage, and supporting cellular recovery following injury. In contrast, nuclear CLU has been associated with DNA damage responses and programmed cell death, highlighting the context-dependent nature of CLU signaling. Mechanistic studies have shown that CLU can influence major survival pathways, including PI3K/AKT, ERK1/2, NF-κB, and apoptosis-related networks. Through interactions with proteins such as Ku70, Bax, and components of the complement system, CLU helps determine whether stressed cells adapt, survive, or undergo apoptosis. This dual role as both a protective factor and a regulator of cell fate explains why CLU expression is tightly controlled under physiological conditions and frequently dysregulated in disease states.
The clinical significance of CLU extends across oncology, neurodegenerative disorders, kidney disease, metabolic dysfunction, cardiovascular pathology, and ocular diseases. In cancer, elevated CLU expression is often associated with tumor progression, therapeutic resistance, metastatic potential, and poor clinical outcomes, making it an attractive target for combination therapies aimed at overcoming drug resistance. In neurodegenerative diseases such as Alzheimer's disease, CLU has been linked to amyloid processing, neuroinflammation, and neuronal survival, and genetic studies consistently identify CLU as an important risk-associated factor. Emerging evidence also highlights a protective role for CLU in kidney injury, where reduced CLU activity may impair tissue repair and accelerate fibrosis, while increased expression frequently accompanies renal stress and damage. Because CLU sits at the intersection of protein quality control, inflammation, apoptosis, and tissue regeneration, it is increasingly regarded as a cross-disease molecular regulator with strong potential as both a diagnostic biomarker and a next-generation therapeutic target for complex chronic disorders.
Alternate Names for CLU
CLU; clusterin; CLI; AAG4; APOJ; CLU1; CLU2; KUB1; SGP2; APO-J
Loading ......
